Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.7 GBX | +0.36% | +2.78% | +16.63% |
Jul. 02 | Creo extends contract; Belluscura raises funds | AN |
Jul. 02 | HVIVO plc Announces Change of Registered Address | CI |
Business Summary
The Group's fast-growing services business includes a unique portfolio of 11 human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.
hVIVO plc runs challenge trials in London with a new 50 quarantine bedroom, state-of-the-art facilities opening in Canary Wharf in 2024, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.
Number of employees: 274
Sales per Business
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Contract Research Organisation Pharmaceutical Services
95.5
%
| 48 | 95.6 % | 56 | 95.5 % | +15.61% |
Other
4.5
%
| 2 | 4.4 % | 3 | 4.5 % | +18.15% |
Sales per region
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom, Ireland, France and Netherlands
100.0
%
| 51 | 100.0 % | 59 | 100.0 % | +15.72% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Yamin Khan
CEO | Chief Executive Officer | 55 | 21-10-12 |
Ian O'Connell
FOU | Founder | 37 | 11-01-31 |
Cathal Friel
FOU | Founder | 59 | 11-01-31 |
Director of Finance/CFO | 61 | 17-06-30 | |
Adam French
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
Mariya Kalinova
CTO | Chief Tech/Sci/R&D Officer | - | 14-03-31 |
Andrew Catchpole
CTO | Chief Tech/Sci/R&D Officer | - | 20-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-06-07 | |
Cathal Friel
FOU | Founder | 59 | 11-01-31 |
Brendan Buckley
FOU | Founder | 73 | 18-11-30 |
Elaine Sullivan
BRD | Director/Board Member | 63 | 20-11-23 |
Yamin Khan
CEO | Chief Executive Officer | 55 | 21-10-12 |
Director of Finance/CFO | 61 | 17-06-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 680,371,877 | 391,922,887 ( 57.60 %) | 0 | 57.60 % |
Company contact information
Sector
Sales per Business
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+16.63% | 240M | |
+18.97% | 44.44B | |
+41.98% | 40.03B | |
-10.06% | 37.68B | |
+31.15% | 31.46B | |
-7.79% | 27.29B | |
+13.32% | 26.29B | |
+43.05% | 13.8B | |
+31.28% | 12.46B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- VENN Stock
- Company hVIVO plc